Development of Oral Agent in the Treatment of Multiple Sclerosis: How the First Available Oral Therapy, Fingolimod Will Change Therapeutic Paradigm Approach

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2012 Aug 14

PMID 22888218

Citations 12

Authors

Claudio Gasperini

Serena Ruggieri

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, traditionally considered to be an autoimmune, demyelinating disease. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. At present, there are five licensed first-line disease-modifying drugs and two second-line treatments in MS. Currently available MS therapies have shown significant efficacy throughout many trials, but they produce different side-effect profiles in patients. Since they are well known and safe, they require regular and frequent parenteral administration and are associated with limited long-term treatment adherence. Thus, there is an important need for the development of new therapeutic strategies. Several oral compounds are in late-stage development for treating MS. Fingolimod (FTY720; Novartis, Basel, Switzerland) is an oral sphingosine-1-phosphase receptor modulator which has demonstrated superior efficacy compared with placebo and interferon β-1a in Phase III studies and has been approved in the treatment of MS. We summarily review the oral compounds in study, focusing on the recent development, approval and the clinical experience with FTY720.

Citing Articles

Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis.

Wang P, Jiang F, Zeng Q, Yin W, Hu Y, Li Q J Neuroinflammation. 2024; 21(1):28.

PMID: 38243312 PMC: 10799425. DOI: 10.1186/s12974-024-03016-8.

Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?.

Witman Tsur S, Zaher E, Tsur M, Kania K, Kalinowska-Lyszczarz A Int J Mol Sci. 2021; 22(8).

PMID: 33917860 PMC: 8068297. DOI: 10.3390/ijms22083859.

Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes.

Kwiatkowski A, Stewart J, Cho J, Avram D, Keselowsky B Adv Healthc Mater. 2020; 9(11):e2000164.

PMID: 32519501 PMC: 7588284. DOI: 10.1002/adhm.202000164.

An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Cho J, Stewart J, Drashansky T, Brusko M, Zuniga A, Lorentsen K Biomaterials. 2017; 143:79-92.

PMID: 28772190 PMC: 5870833. DOI: 10.1016/j.biomaterials.2017.07.029.

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients.

Farrokhi M, Amani Beni A, Etemadifar M, Rezaei A, Rivard L, Rafiee Zadeh A Int J Prev Med. 2016; 6:125.

PMID: 26900439 PMC: 4736130. DOI: 10.4103/2008-7802.172539.

References

Ockenfels H, Schultewolter T, Ockenfels G, Funk R, Goos M . The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998; 139(3):390-5. DOI: 10.1046/j.1365-2133.1998.02400.x. View

Confavreux C, Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain. 2006; 129(Pt 3):606-16. DOI: 10.1093/brain/awl007. View

Kappos L, Gold R, Miller D, MacManus D, Havrdova E, Limmroth V . Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008; 372(9648):1463-72. DOI: 10.1016/S0140-6736(08)61619-0. View

Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A . FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2006; 2(6):439-48. View

Takabe K, Paugh S, Milstien S, Spiegel S . "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008; 60(2):181-95. PMC: 2695666. DOI: 10.1124/pr.107.07113. View

Frohman E, Racke M, Raine C . Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med. 2006; 354(9):942-55. DOI: 10.1056/NEJMra052130. View

Weinshenker B, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J . The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989; 112 ( Pt 1):133-46. DOI: 10.1093/brain/112.1.133. View

Brinkmann V . Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007; 115(1):84-105. DOI: 10.1016/j.pharmthera.2007.04.006. View

Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M . Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006; 13(6):604-10. DOI: 10.1111/j.1468-1331.2006.01292.x. View

10.

Oo M, Thangada S, Wu M, Liu C, Macdonald T, Lynch K . Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007; 282(12):9082-9. DOI: 10.1074/jbc.M610318200. View

11.

Kappos L, Antel J, Comi G, Montalban X, OConnor P, Polman C . Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355(11):1124-40. DOI: 10.1056/NEJMoa052643. View

12.

OConnor P, Comi G, Montalban X, Antel J, Radue E, de Vera A . Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009; 72(1):73-9. DOI: 10.1212/01.wnl.0000338569.32367.3d. View

13.

Brinkmann V . FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009; 158(5):1173-82. PMC: 2782328. DOI: 10.1111/j.1476-5381.2009.00451.x. View

14.

OConnor P, Li D, Freedman M, Bar-Or A, Rice G, Confavreux C . A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006; 66(6):894-900. DOI: 10.1212/01.wnl.0000203121.04509.31. View

15.

Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R . Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo). 1994; 47(2):208-15. DOI: 10.7164/antibiotics.47.208. View

16.

Chun J, Hartung H . Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010; 33(2):91-101. PMC: 2859693. DOI: 10.1097/WNF.0b013e3181cbf825. View

17.

Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S . Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003; 305(1):70-7. DOI: 10.1124/jpet.102.045658. View

18.

Galetta S, Markowitz C . US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs. 2005; 19(3):239-52. DOI: 10.2165/00023210-200519030-00005. View

19.

Murray T . Diagnosis and treatment of multiple sclerosis. BMJ. 2006; 332(7540):525-7. PMC: 1388131. DOI: 10.1136/bmj.332.7540.525. View

20.

Kovarik J, Slade A, Riviere G, Neddermann D, Maton S, Hunt T . The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. Br J Clin Pharmacol. 2008; 66(2):199-206. PMC: 2492924. DOI: 10.1111/j.1365-2125.2008.03199.x. View